Skip to content
Get started

🚀 

A New Dawn for Rare Disease Treatments in the UK: What the MHRA Announcement Means

A major signal of change has arrived for the UK rare disease community. On 2 November 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) published a policy paper promising sweeping reforms to how rare disease therapies are regulated — reforms designed to speed up access, cut red tape, and reflect the realities of very small patient populations. 

Here’s what this could mean for patients, researchers, and the wider NHS — and why it matters so much.

Why This Matters

  1. Rare Diseases Are Commoner Than You Think

    • According to the MHRA, around 3.5 million people in the UK — around one in 17 — live with a rare disease.

    • Yet, fewer than 5% of rare diseases currently have an approved treatment. 

    • The diagnostic journey can be painfully slow: on average, it takes 5.6 years for a diagnosis, and tragically, 30% of children with rare diseases die before they turn five. 

    • Beyond the human cost, there’s a huge economic burden: delayed diagnosis and lack of treatment are estimated to cost £340 million annually, plus £4.7 billion in disability costs and up to £14.9 billion in wider economic losses. 

  2. Why Regulators Have Struggled

    • Traditional clinical trial and licensing models are often ill-suited to rare diseases. Because patient groups are small, trials can be hard to run; evidence is often sparse; and the usual pathways (designed for common conditions) don’t always work. 

    • Advanced therapies — like gene therapies, mRNA treatments, and CRISPR-based interventions — present additional challenges: manufacturing complexity, long-term safety, and highly personalised treatment designs. 

What the MHRA Is Proposing

The MHRA’s paper (titled “Rare therapies and UK regulatory considerations”) lays out a visionary, more flexible regulatory framework to tackle these bottlenecks.  Some of the key proposals include:

  1. Flexible Licensing / Approval Routes

    • Considering single authorisations that would cover both clinical trial applications and marketing authorisations, even when the available data is still limited. 

    • These “early but conditional” approvals would be paired with strict post-marketing safety monitoring and real-world data collection. 

    • For highly personalised therapies (even therapies tailored to one individual), the MHRA is exploring whether a single licence could be granted even if the therapy has a variable component.

  2. Innovative Evidence Generation

    • Use of adaptive trial designs (e.g., Bayesian trials, platform trials, N-of-1 studies) to make the most of small patient populations. 

    • Rely more on natural history data and real-world evidence when randomized controlled trials are not feasible. 

    • Use of surrogate endpoints to speed up development, with the caveat of building in confirmatory follow-up studies. 

  3. Stronger Post-Market Surveillance

    • Once a rare therapy is on the market, there would be mandatory long-term follow-up to ensure patient safety and to collect further efficacy data. 

    • The MHRA also intends to pool data internationally (sharing evidence across countries) to strengthen monitoring and understanding of rare therapies. 

  4. Patient Involvement & Transparency

    • Patients and their advocates will be deeply involved in shaping the framework. The MHRA emphasises that patient perspectives must feed into how risk vs. benefit decisions are made. 

    • The new regulatory model aims for transparency about uncertainties, ongoing monitoring, and risk communication. 

  5. Timeline & Process

    • Public consultation on this framework is due to start in early 2026, with the goal of a refined, implementable model by late 2026. 

    • There’s a Rare Disease Consortium supporting this work, involving regulators, patient groups, academia, and industry. 

What Stakeholders Are Saying

  • Patient groups:

    • Genetic Alliance UK pointed out how many families are left without any treatment options — this reform could be a “vital step” toward real change. 

    • Beacon, a rare-disease charity, said the initiative brings hope. They particularly welcomed the idea of real-world data playing a bigger role. 

  • Industry & Research:

    • Cell & Gene Therapy Catapult supports the move for more “science-led, flexible” approval pathways, noting the huge potential of therapies like CRISPR or mRNA for rare disease. 

    • LifeArc emphasises urgency: “For people living with rare diseases, every moment counts.” They see this as an opportunity to build the UK into a global hub for rare-disease innovation. 

Challenges & Risks to Watch

While this is a bold and exciting proposal, there are some real challenges ahead:

  1. Regulatory Risk vs. Patient Safety

    • Granting approvals on limited data is risky. The success of this strategy depends heavily on robust post-marketing surveillance and strong real-world evidence systems.

    • Balancing speed and safety will be crucial: regulators must ensure that early access doesn’t come at the cost of exposing patients to unanticipated harms.

  2. Data Infrastructure

    • Collecting and analyzing real-world data (RWD) requires sophisticated infrastructure, especially for rare diseases where patient numbers are low.

    • Pooling data internationally is critical — but this requires alignment across countries, data privacy safeguards, and shared standards.

  3. Sustainability & Cost

    • Rare therapies are often expensive to develop and manufacture. There needs to be clarity on how these will be paid for, how the NHS will manage them, and how regulators can ensure both access and affordability.

    • Long-term follow-up adds additional cost and administrative burden.

  4. Patient Involvement

    • While patient involvement is promised, ensuring that it is meaningful (not just token) is vital. The perspectives of patients should genuinely shape the framework, not just be included for optics.

    • There may be tensions between regulatory cautiousness and the urgency felt by patient communities.

Why This Is a Potentially Transformative Moment

  • Leadership: The UK potentially positions itself as a global leader in rare disease therapy regulation — leveraging its NHS, data assets, academic strengths, and regulatory ambition. 

  • Innovation: By supporting flexible, modern trial designs and more personalized therapies, the MHRA could unlock treatments that previously wouldn’t have been viable.

  • Equity & speed: For patients with rare diseases, time is often the enemy. Faster access could make a real difference to lives — especially for children and ultra-rare conditions.

  • Future-proofing: Rather than just retrofitting old regulatory models, MHRA seems to be redesigning them for the next generation of medicines (gene, cell, personalised therapies).

Conclusion

The MHRA’s proposed reforms are a beacon of hope for the rare disease community. They signal a willingness to modernise, to embrace innovation, and to put patients at the centre. If executed well, this could not only speed up access to lifesaving therapies — but also help ensure that the UK remains at the cutting edge of rare disease science.

Nevertheless, bold ideas need rigorous follow-through. Success will depend on clear regulation, excellent data systems, and real collaboration between regulators, patients, researchers, and industry. But the direction is promising — and for many families living with rare diseases, it may finally feel like the system is catching up.

At Regvista, we remain committed to support biopharmaceutical leaders navigating their transformative journey—bringing cutting-edge therapies to market faster and safer. Please feel free to contact us by submitting your enquiry to deployment@regvista.co.uk